Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Alcohol kills – and in this case, that could be a good thing.
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Bayer has responded to its current woes by going all in on cell therapy – a move that, even if successful, will take a long time to pay off.
Trying a different primary endpoint did not help Entresto in heart failure with preserved ejection fraction, but Novartis seemingly still sees a path forward.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.